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Cdh1 is a coactivator of the anaphase-promoting complex/cyclosome (APC/C) and contributes to mitotic exit
and G1 maintenance by facilitating the polyubiquitination and subsequent proteolysis of specific substrates.
Here, we report that budding yeast Cdh1 is a component of a cell cycle-regulated complex that includes the
14-3-3 homologs Bmh1 and Bmh2 and a previously uncharacterized protein, which we name Acm1 (APC/CCdh1
modulator 1). Association of Cdh1 with Bmh1 and Bmh2 requires Acm1, and the Acm1 protein is cell cycle
regulated, appearing late in G1 and disappearing in late M. In acm1 strains, Cdh1 localization to the bud
neck and association with two substrates, Clb2 and Hsl1, were strongly enhanced. Several lines of evidence
suggest that Acm1 can suppress APC/CCdh1-mediated proteolysis of mitotic cyclins. First, overexpression of
Acm1 fully restored viability to cells expressing toxic levels of Cdh1 or a constitutively active Cdh1 mutant
lacking inhibitory phosphorylation sites. Second, overexpression of Acm1 was toxic in sic1 cells. Third, ACM1
deletion exacerbated a low-penetrance elongated-bud phenotype caused by modest overexpression of Cdh1.
This bud elongation was independent of the morphogenesis checkpoint, and the combination of acm1 and
hsl1 resulted in a dramatic enhancement of bud elongation and G2/M delay. Effects on bud elongation were
attenuated when Cdh1 was replaced with a mutant lacking the C-terminal IR dipeptide, suggesting that
APC/C-dependent proteolysis is required for this phenotype. We propose that Acm1 and Bmh1/Bmh2 consti-
tute a specialized inhibitor of APC/CCdh1.
Ubiquitin-mediated proteolysis of key proteins plays a crit-
ical role in regulating cell cycle progression in eukaryotes. This
proteolysis is directed primarily by the activity of two large E3
ubiquitin protein ligase complexes, the Skp1/cullin/F-box pro-
tein (SCF) complex and the anaphase-promoting complex/
cyclosome (APC/C) (57). Important roles for APC/C include
triggering the onset of anaphase and facilitating mitotic exit by
targeting the anaphase inhibitor securin and mitotic cyclins,
respectively, for proteolysis (13, 49, 59). APC/C also helps
establish and maintain the G1 state until conditions are appro-
priate to begin another round of cell division (23, 24).
APC/C is present constitutively during the cell cycle; how-
ever, its activity is thought to be limited to the interval from
early M through late G1 and is directed to substrate proteins in
a highly selective manner. The temporal regulation and sub-
strate specificity of APC/C are attributed to a conserved family
of WD40 repeat-containing proteins that includes Cdc20 (also
called fizzy) and Cdh1 (fizzy related) (29, 46, 56, 60). These
proteins are required to activate APC/C at specific times dur-
ing the cell cycle. Although the mechanism of activation is a
subject of debate, the most widely accepted models propose
that Cdc20 family members contribute to substrate recruitment
by directly binding to specific substrates, either independently
of APC/C or in complex with APC/C (10, 16, 28, 36).
Phosphorylation of Cdh1 is critical for regulating its ability
to activate APC/C and thereby restricting activity to a specific
period of the cell cycle. APC/CCdh1 is inactivated at the G1/S
boundary when cyclin-dependent kinase (CDK) activity phos-
phorylates Cdh1, preventing it from associating with APC/C
(26, 30, 60). In budding yeast, Cdh1 phosphorylation also
results in its export from the nucleus to the cytoplasm (25).
In late anaphase, Cdc14 phosphatase is activated and de-
phosphorylates Cdh1, allowing it to reactivate APC/C and
promote mitotic exit (26, 55). APC/CCdh1 also triggers the
inactivation of APC/CCdc20 by targeting Cdc20 for degrada-
tion in late M (50).
An interesting question regarding regulation of Cdh1 is why
its level remains relatively high from S through M phase when
APC/CCdh1 activity is absent (30, 31, 40). In budding yeast, the
Cdh1 protein level appears low when cells are arrested in G1
with the -factor mating pheromone but is elevated in S phase
and M phase (23, 25, 40, 60). In vertebrate systems, Cdh1 is
reported to target itself for proteolysis during G1, effectively
reducing its level and contributing to its own inactivation (31).
Its level then increases during the subsequent S phase and
peaks during mitosis. There are no defined functions for Cdh1
during this cell cycle interval when APC/CCdh1 activity is
turned off, although one report has implicated Cdh1 in a G2
DNA damage checkpoint response in vertebrate cells (52).
Since several reports demonstrate that Cdh1 can interact with
its substrates independently of APC/C (9, 10, 28, 38, 47), the
issue of its fate following G1 exit is important because it could
potentially influence or interfere with the normal function of
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its substrates during this time. In higher eukaryotes, two pro-
teins that inhibit Cdh1 through physical association, Emi1
(Rca1 in Drosophila) (20, 41) and Mad2B (12, 39), have been
described. The biological function of Mad2B is unclear, but
evidence suggests that Emi1 and Rca1 are required for proper
inactivation of APC/CCdh1 at the end of G1 and in G2, respec-
tively. Emi1 has been proposed to act by inhibiting substrate
binding to Cdh1 (41). To date, similar Cdh1-bound inhibitors
of APC/C activity have not been found in yeast.
To further understand the fate of budding yeast Cdh1 fol-
lowing its nuclear export and inactivation, we sought to identify
proteins that stably associate with it. In this paper, we report
the identification of a stable protein complex containing Cdh1,
the 14-3-3 homologs Bmh1 and Bmh2, and a previously un-
characterized protein. This complex is strictly cell cycle regu-
lated, appearing in late G1 and disappearing in late M, corre-
sponding to the cell cycle interval in which APC/CCdh1 is
inactive. Our results are consistent with this complex acting as
a specialized inhibitor of APC/CCdh1 activity and further imply
that Cdh1 function might be required under specific conditions
during S and/or M phase.
MATERIALS AND METHODS
Reagents. EZview anti-FLAG M2 and anti-hemagglutinin (HA)-7 affinity res-
ins and anti-FLAG M2 antibody were from Sigma. Anti-HA 12CA5 antibody was
from Roche Applied Science. Rabbit anti-Clb2, goat anti-Cdc20, and goat anti-
Cdc28 antibodies were from Santa Cruz Biotechnology. Ase1 polyclonal anti-
body was a generous gift from David Pellman (Harvard University). Fluorescent
anti-mouse, anti-rabbit, and anti-goat secondary antibodies for imaging with the
LI-COR Odyssey system were from Molecular Probes or Rockland Immuno-
chemicals.
Standard yeast medium was used for cell growth. YPD contained 20 g/liter
dextrose, 20 g/liter peptone, and 10 g/liter yeast extract. Selective medium con-
tained 20 g/liter dextrose, 6.7 g/liter yeast nitrogen base, and the appropriate
amino acid dropout mixture. For experiments requiring galactose induction,
liquid selective medium contained 2% raffinose and agar plates contained 2%
galactose in place of dextrose as the carbon source.
Chemicals for cell cycle arrest were -factor peptide (GenScript Corp.), hy-
droxyurea (HU; Sigma), and nocodazole (EMD Biosciences). Sytox green dye
for flow cytometry was from Molecular Probes. Sequencing grade porcine trypsin
was from Promega. The ProteoSilver staining kit used was from Sigma.
Strain and plasmid constructions. All strains (Table 1) were from the W303
or the BY4741 background. Many experiments were performed in both back-
grounds and always yielded similar results. Complete-gene deletions were gen-
erated by standard PCR-based approaches (7). Chromosomal alleles encoding
amino-terminal 3HA or 3FLAG epitope fusion proteins were generated as
previously described (44). Gene deletions were confirmed by PCR. Introduction
of epitope tags was confirmed by PCR, DNA sequencing, and Western blotting.
Plasmid pMPY-3xFLAG for construction of strains expressing endogenous
proteins with amino-terminal 3FLAG tags was created by replacing the 3HA





annealed, and the 3 ends were extended with Klenow DNA polymerase. The
product was digested with NotI and ligated into the NotI sites of pMPY-3xHA to
replace the 3HA sequence upstream of URA3. The same product was then
digested with EcoRI and XhoI and ligated into the EcoRI/XhoI-treated plasmid
generated in the previous step to replace the 3HA sequence downstream of
URA3. The same primers used to amplify the integrating DNA from pMPY-
3xHA (44) were also used for pMPY-3xFLAG.
The following plasmids are derivatives of centromeric plasmid p415ADH (34).
pHLP130 (formerly p415ADH-FLAGCdh1), expressing 3FLAG-CDH1 from the
ADH promoter, was constructed previously (21). pHLP117, expressing 3HA-
ACM1 from the natural ACM1 promoter, was created by first digesting
p415ADH with SacI and XbaI to excise the ADH promoter, treating the remain-
ing vector product with mung bean nuclease to create blunt ends, and religating.
Into the SmaI and PstI sites of this vector, we subcloned 3HA-ACM1 with roughly
700 bp of 5 flanking sequence that had been amplified by PCR from YKA226
genomic DNA. Cell cycle-regulated expression similar to that of endogenous
ACM1 was confirmed by Western blotting. To create pHLP114 expressing
3FLAG-CDH1-EGFP from the ADH promoter, we first subcloned the CDH1
TABLE 1. Yeast strains used in this study
Name Relevant genotype Source or reference
W303 background
YKA150 MATa bar1::URA3 21
YKA247 MATa bar1::URA3 acm1::KanMX4 This study
DLY3033 MATa bar1::URA3 cdc15-2 Daniel Lew, Duke University
BY4741 background
YKA226 MATa 3HA-ACM1 This study
YKA227 MATa bar1::URA3 3HA-ACM1 This study
YKA233 MATa bar1::hisG This study
YKA237 MATa bar1::hisG acm1::URA3 This study
YKA245 MATa bar1::URA3 3HA-ACM1 cdh1::KanMX4 This study
YKA249 MATa bar1::hisG 3HA-BMH1 This study
YKA250 MATa bar1::hisG 3HA-CDH1 This study
YKA252 MATa bar1::hisG 3HA-HSL1 This study
YKA255 MATa bar1::hisG swe1::KanMX4 acm1::URA3 This study
YKA256 MATa bar1::hisG 3HA-CDH1 acm1::KanMX4 This study
YKA257 MATa bar1::hisG 3HA-HSL1 acm1::KanMX4 This study
YKA258 MATa bar1::hisG hsl1::KanMX4 acm1::URA3 This study
YKA259 MATa bar1::hisG clb2::KanMX4 acm1::URA3 This study
YKA274 MATa bar1::hisG 3HA-BMH1 acm1::KanMX4 This study
YKA290 MATa bar1::hisG 3FLAG-CDH1 3HA-ACM1 This study
YKA291 MATa bar1::hisG 3FLAG-CDH1 This study
BY4741 hsl1 MATa hsl1::KanMX4 Open Biosystems
BY4741 clb2 MATa clb2::KanMX4 Open Biosystems
BY4741 bmh1 MATa bmh1::KanMX4 Open Biosystems
BY4741 bmh2 MATa bmh2::KanMX4 Open Biosystems
BY4741 sic1 MATa sic1::KanMX4 Open Biosystems























coding sequence into the BamHI and SalI sites of pESC-EGFP (a gift from H.
Charbonneau) to create the CDH1-EGFP fusion. A HindIII/XhoI fragment from
this plasmid was then subcloned into pHLP130. The QuikChange site-directed
mutagenesis system (Stratagene) was used to delete the last two codons of CDH1
from pHLP130, creating the 3FLAG-CDH1IR allele (pHLP120).
The following are all centromeric galactose-inducible expression plasmids.
3FLAG-ACM1 was amplified by PCR from another construct and subcloned into
the XbaI and XhoI sites of p416GAL1 (URA3) to create pHLP112. ACM1 was
amplified from yeast genomic DNA with a forward primer containing a single
HA epitope sequence and subcloned into the XbaI and XhoI sites of p415GAL1
(LEU2) to create pHLP109. pHLP163 (previously called pNC219-FLAGCdh1),
expressing 3FLAG-CDH1 from the GAL1 promoter and carrying the TRP1
selectable marker, was described previously (21). Site-directed mutagenesis was
used to create the cdh1-m11 mutant allele in pHLP163. The 3FLAG-cdh1-m11
allele was excised by digestion with XbaI and XmaI and subcloned into the XbaI
and XmaI sites of p415GALS (LEU2) to create pHLP154. 3FLAG-Cdh1 was
excised from pHLP130 by XbaI and XhoI digestion and subcloned into the XbaI
and XhoI sites of p415GAL1 (LEU2) to create pHLP162. All plasmid construc-
tions involving PCR were verified by DNA sequencing of the amplified region.
Cell growth, arrests, and synchronization. Synchronized cultures were gener-
ated by block and release with 5 g/ml -factor or 15 g/ml nocodazole as
previously described (2). Arrest was monitored by microscopy until 95% of the
cells exhibited the desired morphology. After release, aliquots were removed at
the desired time points for flow cytometry and immunoblotting analysis. For
immunoblotting, samples from each time point were resuspended at identical cell
densities in sodium dodecyl sulfate (SDS) loading dye, boiled for 5 min, dis-
rupted for 5 min by vortexing with glass beads, and cleared by centrifugation.
Cells were arrested in G1 by -factor treatment (50 g/liter for bar1 and 5
g/ml for BAR1 strains), in S with 10 mg/ml HU, in G2/M with 15 g/ml
nocodazole, or in late M (with a cdc15-2 strain) by shifting growth from 25°C to
37°C. Arrests were confirmed by visual inspection of cell morphology by phase-
contrast microscopy or by flow cytometry.
For microscopic examination of cell morphology, liquid cultures were grown at
30°C to saturation in selective medium and then diluted to an optical density at
600 nm of 0.05 to 0.1 in YPD. Cultures were allowed to pass through several
divisions at 30°C before harvesting at an optical density at 600 nm of 0.6 to 0.8
for analysis by microscopy, flow cytometry, and immunoblotting. For localization
experiments, selective medium was used exclusively, except for nocodazole ar-
rest, which requires growth in YPD. Otherwise, the growth procedure was the
same.
Immunoaffinity purification of protein complexes. 3FLAG-Cdh1 and 3HA-
Acm1 were purified from yeast extracts by the same procedure. Frozen cell
pellets were thawed on ice; resuspended in 2 volumes of buffer L (50 mM sodium
phosphate [pH 7.5], 400 mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.5 mM
dithiothreitol, 50 mM sodium fluoride, 50 mM -glycerophosphate) supple-
mented with 1 mM phenylmethylsulfonyl fluoride, 1 M pepstatin, 100 M
leupeptin, and 5 mM EDTA; and distributed into 1.5-ml microcentrifuge tubes.
Glass beads were added to half of the total liquid volume, and cells were agitated
in a Disruptor Genie (Scientific Industries) until greater than 75% of the cells
were lysed (typically, 15 to 20 min). Extracts were cleared by centrifugation at
16,000  g in a microcentrifuge for 30 min, and the contents of each tube were
pooled. Anti-FLAG or anti-HA resin was added to the soluble extracts (approx-
imately 1 l/5 mg protein), and the mixture was incubated on a rotating platform
for 2 h at 4°C. Resin was washed four times with 25 ml buffer L. Bound protein
was eluted twice with 250 g/ml 3FLAG peptide or HA peptide (Sigma) in buffer
L for 20 min at 30°C. Elutions were combined and separated by SDS-polyacryl-
amide gel electrophoresis (PAGE) on 4 to 12% gradient gels (Bio-Rad), and
proteins were visualized by staining with silver or Coomassie blue.
MS. SDS-PAGE bands were excised, destained, and subjected to in-gel diges-
tion overnight at 37°C with 20 g/ml trypsin in fresh 50 mM ammonium bicar-
bonate. Extracted peptides were analyzed on an Applied Biosystems 4700 ma-
trix-assisted laser desorption ionization–tandem time of flight mass spectrometer
in positive reflectron mass spectrometry (MS) and tandem MS modes. Combined
MS and tandem MS database searches were performed with GPS Explorer
software (Applied Biosystems) and the Mascot search engine (Matrix Science).
For each protein identification, a single statistically significant score was obtained
from Saccharomyces cerevisiae, with the exception of Bmh1 and Bmh2, which
cross-matched because of their 93% sequence identity. However, peptides
unique to both Bmh1 and Bmh2 were detected and confirmed by tandem MS.
Co-IP and Western blotting. Coimmunopurification (Co-IP) experiments were
performed essentially as described above for purifications of the Cdh1 complex.
For Cdh1-substrate Co-IPs, buffer C (50 mM sodium phosphate [pH 7.5], 100
mM NaCl, 10% glycerol, 0.1% Triton X-100, 5 mM EDTA) was used. For
Cdh1-Acm1 and Cdh1-Bmh1 Co-IPs, buffer L was used. The signal from immu-
noblots was visualized with ECL Plus reagents (GE Healthcare) or directly with
a LI-COR Odyssey infrared imaging system. For quantification, immunoblot
signals were analyzed either from films by densitometry on an Alpha Innotech
Corporation Fluorchem imager or with the Odyssey image analysis software.
Flow cytometry. A 500-l volume of mid-log-phase culture was washed with
water and fixed in 70% ethanol overnight at 4°C. Cells were washed again,
treated with 1 mg/ml RNase A in 50 mM Tris-HCl (pH 8)–15 mM NaCl for at
least 2 h at 37°C, treated with 5 mg/ml freshly made pepsin in 0.17% HCl for not
more than 20 min, washed with 50 mM Tris-HCl (pH 8), and suspended in 1 M
Sytox green in 50 mM Tris-HCl (pH 8). Cells were briefly sonicated immediately
prior to analysis on a Beckman Coulter Cytomics FC 500 flow cytometer.
Microscopy. Fluorescence and differential interference contrast (DIC) micro-
scope images were acquired on a Leica DMRX HC microscope equipped with a
Hamamatsu ORCA ER digital camera and OpenLab software (Improvision
Inc.). All images in a given experiment were acquired with identical microscope
and camera settings, and any additional image processing was applied to all
images with ImageJ or Adobe Photoshop software. The relative intensity of bud
neck-specific green fluorescent protein fluorescence signal in raw image files was
determined with ImageJ by measuring the average pixel density in an area
demarcating the visible bud neck band and subtracting the average pixel density
in an equivalent area of adjacent cytoplasm. The resulting values from 20 ran-
domly selected cells that showed visible bud neck-specific fluorescence in wild-
type and acm1 strains were then averaged. Cells were fixed with formaldehyde
for all microscopy experiments.
To prepare cells for indirect immunofluorescence, spheroplasts were gener-
ated essentially as previously described (8) and spotted on poly-L-lysine-treated
slides. After a 15-min incubation at room temperature (RT), slides were sub-
merged first in methanol (	20°C) for 6 min and second in acetone (	20°C) for
30 s and air dried. Samples were incubated in blocking solution (0.1 mg/ml
streptavidin and 3% bovine serum albumin [BSA] in phosphate-buffered saline–
Tween 20 [PBS-T]) at 4°C for 1 h and then in anti-HA 12CA5 antibody (Roche)
diluted 1:500 in PBS-T containing 0.5 mg/ml D-biotin and 3% BSA for 1 h at RT.
Slides were washed three times for 5 min with PBS-T and then incubated with
biotin-conjugated anti-mouse immunoglobulin G (Vector Laboratories) diluted
1:200 in PBS-T containing 3% BSA at RT for 30 min. Slides were washed again
three times for 5 min with PBS-T. Finally, slides were incubated with streptavi-
din-conjugated Alexa Fluor 488 (Molecular Probes) diluted 1:200 in PBS-T
containing 3% BSA for 30 min at RT and washed three times for 5 min with
PBS-T.
RESULTS
Cdh1 stably interacts with three other proteins. We used
immunoaffinity purification and MS to identify proteins asso-
ciated with Cdh1 during cell cycle stages when APC/CCdh1
activity is thought to be absent. 3FLAG epitope-tagged Cdh1
was purified from yeast extracts with anti-FLAG affinity resin,
and eluted proteins were visualized by SDS-PAGE (Fig. 1A).
Three additional protein bands were detected specifically in
the presence of 3FLAG-Cdh1 and were identified by peptide
mass fingerprinting and tandem MS. Two of them, Bmh1 and
Bmh2, are homologs of the highly conserved 14-3-3 family. The
third protein is the product of a previously uncharacterized
open reading frame, YPL267W, which we have named Acm1
(APC/CCdh1 Modulator 1). We also used anti-HA affinity resin
to purify endogenous 3HA epitope-tagged Acm1 and any
bound proteins (Fig. 1B). Cdh1, Bmh1, and Bmh2 were iden-
tified by MS, suggesting that Cdh1 associates with Acm1 and
the 14-3-3 proteins in a single complex. However, our data do
not distinguish between Bmh1 and Bmh2 existing together in
the complex as a heterodimer or individually, forming distinct
subcomplexes. We observed the complex by using cells ar-
rested in late M by temperature shift in a cdc15-2 strain (Fig.
1A), in S by HU treatment (Fig. 1B and 2D), and in asynchro-
nous cultures (not shown). The same interacting proteins were
observed when endogenous Cdh1 (not shown) or Cdh1 over-























produced from the ADH promoter was purified and when the
3FLAG tag was at the N terminus or C terminus (not shown)
of Cdh1. The complex is highly salt stable since the purifica-
tions were performed at 500 mM Na.
The Cdh1 protein complex forms in vivo. 14-3-3 proteins are
highly expressed and interact with numerous proteins (54). We
were initially concerned that the complex might be an artifact
of the cell extracts and would not normally exist in vivo. To test
this, we used a method reported previously to confirm in
vivo formation of a Cdc20-CCT chaperonin complex (11).
Side-by-side Co-IPs of endogenous 3HA-Acm1 with endoge-
nous 3FLAG-Cdh1 were performed with either a doubly
tagged strain or a mixture of two singly tagged strains. In the
latter sample, the two tagged proteins can only interact after
cell lysis, whereas in the doubly tagged strain the two tagged
proteins have the opportunity to associate inside the cell prior
to lysis. Figure 1C clearly shows that the interaction between
3HA-Acm1 and 3FLAG-Cdh1 is observed exclusively when
FIG. 1. Cdh1 is a component of a multiprotein complex. (A) 3FLAG-Cdh1 expressed from the ADH promoter on a CEN plasmid (pHLP130)
was purified from a cdc15-2 strain (DLY3033) arrested in late M at 37°C. Eluted proteins were analyzed by SDS-PAGE and Coomassie blue
staining and compared to a control preparation from cells lacking the 3FLAG-Cdh1 expression plasmid. Bands specific to the 3FLAG-Cdh1 sample
were excised and analyzed by MS. Identified proteins are labeled with arrows. m, markers. (B) Endogenous 3HA-Acm1 was purified from strain
YKA226 arrested in S phase with HU and analyzed by SDS-PAGE and silver staining. Bands present in the preparation of 3HA-Acm1 but not
in a control preparation from cells lacking the 3HA epitope tag (BY4741) were excised and analyzed by MS. Note that 3HA-Acm1 and Bmh2
comigrate on this gel but were still both unambiguously identified. (C) Western analysis of endogenous 3HA-Acm1 copurifying with endogenous
3FLAG-Cdh1 from yeast extracts derived either from two mixed cultures (YKA227 and YKA291), each individually expressing one of the tagged
proteins (mixed single tags) or from a single strain (YKA290) expressing both tagged proteins (double tag). The control (Neg Con) sample is
BY4741 lacking the epitope tags. Cdc28 is a loading control. IP, immunoprecipitate. (D) Western blotting was used to quantify the amount of Cdh1
bound to Acm1 in HU-arrested cells. Whole-cell extracts (WCE) containing endogenous 3HA-Acm1 and either endogenous (YKA290) or
overexpressed (pHLP130 in YKA245) 3FLAG-Cdh1 were depleted of 3HA-Acm1 with anti-HA resin. The difference in level of endogenous and
overexpressed 3FLAG-Cdh1 is illustrated in the immunoblot on the left. Codepletion of Cdh1, indicating the amount bound to 3HA-Acm1, was
then measured by anti-FLAG immunoblotting (illustrated on the right) with a LI-COR Odyssey imager. Cdc28 served as a loading control and was
used to normalize the 3HA-Acm1 and 3FLAG-Cdh1 levels in each sample. Different exposures are shown for endogenous and overexpressed
3FLAG-Cdh1 because of the large difference in protein level. The table shows the average depletion of 3HA-Acm1 and codepletion of endogenous
and overexpressed 3FLAG-Cdh1 in three independent experiments with standard deviations. (E) Overexpressed (pHLP130 in YKA245) and
endogenous (YKA290) 3FLAG-Cdh1 were immunopurified from extracts of HU-arrested cells expressing 3HA-Acm1. The amount of copurified
3HA-Acm1 was then monitored by anti-HA immunoblotting. Band intensities were quantified with the LI-COR imager. The ratio of overexpressed
to endogenous immunopurified 3FLAG-Cdh1 was 11 
 4, and the corresponding ratio of copurified 3HA-Acm1 was 12 
 2 (three trials). The
control strain in the No Tag lane was YKA227. (F) Expression of endogenous 3HA-Acm1 (YKA227) and 3HA-Cdh1 (YKA250) was compared
by anti-HA immunoblotting in HU-arrested S-phase cells (HU) and asynchronous log-phase cells (cyc). Cdc28 was a loading control, and the
control strain in the No Tag lane was YKA233.























using the doubly tagged strain, providing strong evidence that
the Cdh1 complex forms in a physiological context in vivo. We
monitored the Acm1-Cdh1 interaction because, as shown in
Fig. 2D and E, association of Bmh1 and Bmh2 with Cdh1 is
dependent on Acm1 and therefore Acm1 binding is a suitable
indicator of full complex assembly.
Acm1, Bmh1, and Bmh2 were observed in roughly stoichi-
ometric amounts in our preparations of 3FLAG-Cdh1 overex-
pressed from the ADH promoter (Fig. 1A), suggesting that
Cdh1 might exist exclusively in complex-bound form at specific
cell cycle stages. We quantified the relative amounts of endog-
enous and overexpressed 3FLAG-Cdh1 present in S-phase
whole-cell extracts prior to and following depletion of endog-
enous 3HA-Acm1 with anti-HA resin (Fig. 1D). 3HA-Acm1
depletion reduced the level of endogenous 3FLAG-Cdh1 by an
average of 87%. When 3FLAG-Cdh1 was overproduced with
the ADH promoter (a roughly 20-fold increase), we still ob-
served a 64% reduction following depletion of endogenous
3HA-Acm1. We also observed a proportionate increase in
3HA-Acm1 copurified with overexpressed 3FLAG-Cdh1 com-
pared to endogenous 3FLAG-Cdh1 (Fig. 1E). Not surprisingly,
immunoblot analysis revealed that endogenous 3HA-Acm1 is
expressed at a much higher level than endogenous 3HA-Cdh1
in both asynchronous and HU-arrested cells (Fig. 1F). To-
gether, these results suggest that Cdh1 is probably stoichio-
metrically associated with the complex, at least during S phase,
and that Acm1, Bmh1, and Bmh2 are not limiting factors in
maintaining Cdh1 in a complexed state.
Acm1 protein is cell cycle regulated. We predicted that if
this Cdh1-bound complex plays a role in regulating APC/CCdh1
activity during the cell cycle, then the complex itself must be
regulated in a cell cycle-dependent manner. Microarray anal-
FIG. 2. The Cdh1 complex is regulated via cell cycle-dependent expression of ACM1. (A) Western analysis of the 3HA-Acm1 level in strain
YKA226 synchronized by -factor block and release. After 45 min, -factor was added back to rearrest in the following G1 phase. The blot was
reprobed with anti-Clb2 for comparison and anti-Cdc28 as a loading control. cyc, cycling asynchronous culture. Samples from each time point were
also analyzed by flow cytometry to monitor cell cycle progression. n, genomic DNA content. (B) A quantitative comparison of 3HA-Acm1 (Œ) and
Clb2 (■ ) levels obtained from the data in panel A by densitometry. The peak level of each protein was normalized to 1. (C) 3HA-Acm1 expressed
from its natural promoter on a single-copy plasmid (pHLP117) in strain YKA247 was monitored by Western blotting in a synchronized culture
released from a nocodazole arrest into medium containing -factor. Immunoblotting of Clb2 was included for comparison. Cell cycle progression
was also monitored by flow cytometry (not shown). (D) 3FLAG-Cdh1 expressed from the ADH promoter on a CEN plasmid (pHLP130) was
purified from the indicated BY4741 yeast strains arrested in S phase with HU. The presence or absence of the other complex components was
monitored by SDS-PAGE and silver staining and confirmed by MS. No Tag, wild-type with empty plasmid. (E) Co-IP of endogenous 3HA-Bmh1
with 3FLAG-Cdh1 expressed from pHLP130 in YKA249 and YKA274 cells containing (wt) or lacking () ACM1, respectively. Anti-FLAG resin
was used for immunopurification, and copurification of Bmh1 was measured by anti-HA immunoblotting. Cyc, asynchronous log-phase cells; G1,
-factor arrest; S, HU arrest; NC, negative control lacking the 3FLAG-Cdh1 expression plasmid; IP, immunoprecipitate.























ysis of yeast gene expression revealed a late G1 transcriptional
peak for ACM1 (YPL267W), and the promoter region of
ACM1 contains SCB and MCB sequence elements character-
istic of numerous genes induced in late G1 (51). Therefore, we
monitored 3HA-Acm1 protein by Western blotting in synchro-
nously growing cultures released either from pheromone-in-
duced G1 arrest or nocodazole-induced M arrest (Fig. 2A to
C). Acm1 is absent from G1 cells. It then appears very quickly
after G1 release, just prior to initiation of DNA replication, as
evidenced by flow cytometry. Acm1 disappears again late in
mitosis around the same time as, or slightly earlier than, the
major mitotic cyclin Clb2. Likewise, following release from a
nocodazole arrest, Acm1 disappeared in late mitosis slightly
earlier than Clb2.
Cdh1-Bmh1/Bmh2 association is Acm1 dependent. To begin
to define the determinants for assembly and regulation of the
Cdh1 complex, we purified 3FLAG-Cdh1 from strains harbor-
ing deletions of the ACM1, BMH1, and BMH2 genes (Fig. 2D).
Strikingly, Bmh1 and Bmh2 were not detected in 3FLAG-
Cdh1 preparations from cells lacking Acm1. In contrast, ab-
sence of Bmh1 or Bmh2 had no effect on the association of the
other three complex components, suggesting that either is suf-
ficient for complex formation. To further confirm the depen-
dence of the Cdh1-Bmh1 interaction on Acm1, we monitored
Co-IP of 3HA-Bmh1 with 3FLAG-Cdh1 using asynchronous
G1- and S-phase cultures (Fig. 2E). As expected, the Cdh1-
Bmh1 interaction was not detected in G1 cells or in the absence
of Acm1. This was true when we used either our typical com-
plex purification buffer containing 500 mM Na (Fig. 2E) or a
more physiological buffer containing 150 mM Na (not
shown). Although we cannot rule out the possibility that ab-
sence of Acm1 weakens a direct Cdh1-Bmh1/Bmh2 association
enough that it is lost during our purification procedure, these
results suggest that Acm1 mediates the association of Cdh1
with Bmh1 and Bmh2.
Cdh1 bud neck localization is enhanced in cells lacking
Acm1. A common function of 14-3-3 proteins is to control
cellular localization of their binding targets, for example, by
sequestering them in the cytoplasm (35). Since Cdh1 is ex-
ported to the cytoplasm at the end of G1 when it is inactivated
(25), we hypothesized that association with Bmh1 and Bmh2
might be required to maintain cytoplasmic localization of Cdh1
during its inactive period. To directly test this, we mimicked
the experimental design of Jaquenoud et al. (25) by expressing
Cdh1 as a C-terminal enhanced green fluorescent protein
(EGFP) fusion (in our case, from the ADH promoter on a
single-copy plasmid) and monitoring its intracellular localiza-
tion in wild-type and acm1 cells at different cell cycle stages
by fluorescence microscopy. In wild-type cells, 3FLAG-Cdh1-
EGFP localized to the nuclei of unbudded cells in an asyn-
chronous population and pheromone-arrested cells and was
primarily dispersed throughout the cytoplasm in cells with
large buds or in cells arrested in M phase with nocodazole (Fig.
3A and B), consistent with the previous results (25). In acm1
cells, 3FLAG-Cdh1-EGFP also localized to the nucleus in G1
and was found dispersed throughout the cytoplasm in large
budded cells (Fig. 3A and B). Therefore, we conclude that
Acm1/Bmh1/Bmh2 is not required to sequester Cdh1 in the
cytoplasm following its inactivation.
Cdh1 was also shown previously to localize to the bud neck
(25). In our analysis of Cdh1 nuclear versus cytoplasmic local-
ization, we observed a dramatic difference in the frequency and
intensity of bud neck staining in acm1 cells compared to the
isogenic wild-type strain (Fig. 3B). In an asynchronous culture,
bud neck staining was observed in both small- and large-bud-
ded cells and was also observed in cells arrested in S with HU
and to a lesser extent in cells arrested in M with nocodazole.
We detected bud neck-specific EGFP signal in only 14% of
budded wild-type cells in an asynchronous culture. In contrast,
bud neck fluorescence was detected in 59% of budded acm1
cells (n  100). After cell cycle arrest with HU, bud neck-
specific EGFP signal was detected in 6% of wild-type cells and
51% of acm1 cells (n  200). Furthermore, the detectable
bud neck-specific fluorescence was sevenfold more intense, on
average, in acm1 cells than in wild-type cells. The average
cytoplasmic fluorescence intensity differed by less than 10%,
and immunoblot assays confirmed equivalent expression of
3FLAG-Cdh1-EGFP in the wild-type and acm1 strains (not
shown).
To rule out the possibility that bud neck localization was an
artifact of Cdh1 overexpression or use of a C-terminal tag, we
used indirect immunofluorescence to visualize endogenous
3HA-Cdh1 localization in wild-type and acm1 cells (Fig. 3C).
A signal amplification strategy (see Materials and Methods)
was required to detect endogenous 3HA-Cdh1 fluorescence.
Consistent with the EGFP experiments, 3HA-Cdh1 localiza-
tion to the bud neck was only detected in acm1 cells. We
conclude that binding of Acm1 and Bmh1/Bmh2 can prevent
localization of Cdh1 to the bud neck.
Specific Cdh1-substrate interactions are enhanced in the
absence of Acm1. Several APC/CCdh1 substrates localize to
the bud neck, including the kinases Hsl1 and Cdc5 (4, 6) and
the mitotic cyclin Clb2 (5, 22). It is possible that localization of
Cdh1 to the bud neck in an acm1 strain was observed because
of enhanced association with one or more of its substrates and
that the complex with Acm1 and Bmh1/Bmh2 functions to
block substrate binding. To test this hypothesis, we compared
the interaction between overexpressed 3FLAG-Cdh1 and sev-
eral of its substrates in acm1 cells and wild-type cells by
Co-IP. The amounts of Clb2 and 3HA-Hsl1 that copurified
with 3FLAG-Cdh1 using asynchronous cultures was between
two- and fourfold higher in the absence of Acm1 after normal-
ization to 3FLAG-Cdh1 (Fig. 4A and B). Using extracts from
asynchronous cultures could be problematic because the pro-
teolytic machinery capable of degrading both Acm1 and the
APC/CCdh1 substrates is likely active. Therefore, we repeated
these experiments after arresting cells in S phase by treatment
with HU. The results were striking. The amounts of Clb2 and
3HA-Hsl1 that copurified with 3FLAG-Cdh1 increased by 25-
fold and more than 100-fold, respectively, in the absence of
Acm1.
Surprisingly, when we probed the same Co-IP samples for
two additional Cdh1 substrates, Ase1 and Cdc20, the results
were very different (Fig. 4A and B). Cdc20 association with
3FLAG-Cdh1 did not increase in the absence of Acm1 in an
asynchronous culture and was enhanced less than threefold in
the absence of Acm1 when cells were treated with HU. Ase1
association with 3FLAG-Cdh1 was undetectable above the
nonspecific background, although the protein produced a very
strong signal in the cell extracts, even in the absence of Acm1.























These results suggest that there may be inherent differences in
the way Clb2 and Hsl1 interact with Cdh1 compared to other
substrates. We also observed a similar enhanced association
with Clb2 in acm1 cells expressing endogenous 3HA-Cdh1
(not shown), ruling out the possibility that these results are
artifacts of Cdh1 overexpression.
Acm1 can suppress APC/CCdh1 activity in vivo. Because
Cdh1 is complexed with Acm1, Bmh1, and Bmh2 during the
same cell cycle interval in which it is thought to be inactive and
because the complex can block association of Cdh1 with cer-
tain substrates, including Clb2, we performed a series of bio-
logical experiments to determine if Acm1 can inhibit APC/
CCdh1 activity in vivo. High-level overexpression of CDH1 from
a GAL promoter results in a G2 cell cycle arrest that has been
attributed to constitutive APC/C activation and depletion of
mitotic cyclins needed to drive mitotic entry (46, 56). We
reproduced this toxic effect of high-level Cdh1 overexpression
with a single-copy plasmid expressing 3FLAG-Cdh1 from the
GAL1 promoter (Fig. 5A). We predicted that if Acm1 acts as
an inhibitor of APC/CCdh1, then co-overexpression of Acm1
might restore viability to these cells. Indeed, co-overexpression
of HA-Acm1 from the GAL1 promoter on a single-copy plas-
mid restored wild-type viability to cells expressing toxic levels
of Cdh1 (Fig. 5A). Second, we tested if Acm1 overexpression
could suppress the toxicity of the Cdh1-m11 mutant (60) that
lacks inhibitory CDK phosphorylation sites. Expression of
3FLAG-Cdh1-m11 at a much lower level from the weak
GALS promoter caused inviability on galactose medium
(Fig. 5B). Overexpression of 3FLAG-Acm1 restored near-
normal viability to these cells. Third, since cells lacking both
Cdh1 and Sic1 are inviable (46, 56), we hypothesized that
overexpression of Acm1 might result in constitutive APC/
CCdh1 inhibition that would lead to low viability in a sic1
background. We observed a severe reduction in viability of
sic1 but not isogenic wild-type cells overexpressing
3FLAG-Acm1 from the GAL1 promoter on a single-copy
plasmid (Fig. 5C). This effect was Cdh1 dependent because
substantial viability was restored by co-overexpression of
3FLAG-Cdh1. Taken together, these results strongly sup-
port the conclusion that Acm1/Bmh1/Bmh2 is an inhibitor
of APC/CCdh1-mediated proteolysis of mitotic cyclins.
Deletion of ACM1 enhances the elongated-bud phenotype of
cells overexpressing Cdh1. While studying Cdh1 localization,
we noticed that many acm1 cells had elongated buds. Since
elongated buds are a hallmark of insufficient mitotic CDK
activity (18, 42) and can be generated by defects in regulators
FIG. 3. Effects of the Cdh1 complex on cellular localization of Cdh1. (A) 3FLAG-Cdh1-EGFP expressed from the ADH promoter (pHLP114)
was visualized with a fluorescence microscope in fixed wild-type (YKA150) or acm1 (YKA247) cells arrested in either G1 with -factor or in M
with nocodazole. (B) Analysis of bud neck localization of 3FLAG-Cdh1-EGFP in wild-type (YKA150) versus acm1 (YKA247) cells in
asynchronous (asynch) and HU-treated cultures. Arrows indicate examples of bud neck localization of 3FLAG-Cdh1-EGFP in the acm1 strain.
(C) Localization of endogenous 3HA-Cdh1 in asynchronous wild-type (YKA250) and acm1 (YKA256) cells was visualized by indirect immu-
nofluorescence by a signal amplification strategy described in Materials and Methods. Bud neck localization of 3HA-Hsl1 in strain YKA252 was
used as a positive control. The immunoblot on the right illustrates the relative 3HA-Cdh1 levels in the wild-type and acm1 strains. Cdc28 was
a loading control. All three images were obtained with a 100 oil immersion objective.























of a bud morphogenesis checkpoint (27), including Hsl1, we
decided to explore this phenotype in more detail. Overexpres-
sion of 3FLAG-Cdh1 from the ADH promoter on a single-copy
plasmid resulted in a low frequency of highly elongated buds
(8.8%) following treatment with HU (Fig. 6A, compare to
panel B). A bud was considered elongated when its length was
at least twice the width of the mother cell, a criterion defined
in a previous study (32). Deletion of ACM1 greatly enhanced
the penetrance of this elongated-bud phenotype (21.1% elon-
gated; Fig. 6B, compare to panel E). In addition, the average
ratio of bud length to mother cell width in cells meeting the
criteria for an elongated bud increased substantially (2.80 for
acm1 versus 2.39 for wild-type). Elongated buds resulting
from defects in regulators of the morphogenesis checkpoint
can typically be suppressed by deletion of SWE1, encoding a
CDK inhibitory kinase (27). SWE1 deletion had no significant
effect on bud elongation associated with Cdh1 overexpression
in acm1 cells (20.4% elongated; Fig. 6E, compare to panel
H), demonstrating that this phenotype is independent of the
morphogenesis checkpoint. To determine if this phenotype
requires APC/CCdh1-dependent proteolysis, we took advantage
of a recently described Cdh1 mutant lacking the last two amino
acids (Cdh1IR) that is defective in APC/C activation but still
able to interact with substrates (10, 37, 58). We confirmed that
Cdh1IR associated with Clb2, similar to Cdh1 (Fig. 6J), and
bound the full Acm1/Bmh1/Bmh2 complex (not shown), dem-
onstrating that the mutation did not globally affect protein
folding or structure. Overexpressed 3FLAG-Cdh1IR did not
elicit an elongated-bud phenotype in wild-type or acm1 cells
(Fig. 6C, F, and I) despite being present at a significantly
higher level than overexpressed wild-type 3FLAG-Cdh1 (Fig.
6K). This observation suggests that hyperpolarized bud growth
promoted by Cdh1 in the absence of Acm1 requires the ability
to activate APC/C-dependent proteolysis and further supports
the conclusion that Acm1 is a negative regulator of mitotic
cyclin proteolysis.
ACM1 and HSL1 interact genetically. We next tested
whether a genetic interaction might exist between ACM1 and
the bud morphogenesis checkpoint that would influence bud
elongation and cell cycle progression by synergistically down-
regulating mitotic CDK activity. We chose to examine Hsl1,
which helps relieve the morphogenesis checkpoint by inactivating
Swe1. We monitored cell elongation in asynchronous cultures and
compared cells containing either the same 3FLAG-Cdh1 over-
expression construct used above or an empty vector. In an
acm1 strain overexpressing Cdh1, 8.2% of the cells were
FIG. 4. The Cdh1 complex can inhibit association of Cdh1 with specific substrates. (A) 3FLAG-Cdh1 expressed from pHLP130 was purified
from mid-log-phase (Asynch) and HU-arrested cultures with anti-FLAG resin. Copurification of APC/C substrates Clb2 and Cdc20 with
3FLAG-Cdh1 from acm1 () and isogenic wild-type (wt) strains (YKA237 and YKA233) was probed by Western blotting with anti-Clb2 or
anti-Cdc20 antibodies. (B) The same experiment as in panel A was performed with acm1 and isogenic wild-type strains expressing a 3HA-HSL1
allele (YKA257 and YKA252). Copurification of 3HA-Hsl1 and Ase1 with 3FLAG-Cdh1 was probed by Western blotting with anti-HA or
anti-Ase1 antibodies. In both panels, NC indicates the negative control lacking the plasmid expressing 3FLAG-Cdh1. Extract immunoblots
demonstrate that roughly equal amounts of substrate were present in all starting samples. Cdc28 was a loading control. Flow cytometry analysis
(bottom of each panel) demonstrates that the cell cycle distribution of acm1 and wild-type cells is not significantly different and confirms the HU
arrests. n, genomic DNA content. Asynch, asynchronous; IP, immunoprecipitate.























elongated (Fig. 7D). hsl1 cells exhibited a mild bud elonga-
tion phenotype (5.2%) that has been reported previously in
some strain backgrounds (33). This phenotype was not en-
hanced by overexpression of 3FLAG-Cdh1 (compare Fig. 7E
and F). Strikingly, the combination of hsl1, acm1, and
3FLAG-Cdh1 overexpression resulted in a dramatic increase
in the severity of bud elongation (Fig. 7H and K). Three-
quarters of these cells met the elongation criteria and, in gen-
eral, they were noticeably larger than those of the other strains
analyzed in this experiment. Liquid cultures grew very slowly
compared to the wild-type and single-deletion strains, and cells
had a greater tendency to clump (data not shown). Consistent
with the HU-treated cultures shown in Fig. 6, the effects of
Cdh1 overexpression were diminished when the 3FLAG-
Cdh1IR mutant was used (data not shown). A clb2 strain
also exhibited a mild bud elongation phenotype, similar to
hsl1 cells and consistent with previous reports (42) (data not
shown). Combining acm1 and 3FLAG-Cdh1 overexpression
with clb2 did not enhance the severity of bud elongation to
the same extent as it did with hsl1 (Fig. 7J and K). So al-
though HSL1 and CLB2 are both components of the morpho-
genesis checkpoint, their genetic interactions with ACM1 are
different. Surprisingly, given the apparent requirement for
APC/C activation by Cdh1 in the experiments described above
and the previous reports of Clb2 depletion in cells overexpress-
ing toxic levels of Cdh1, we did not observe a large reduction
in Clb2 level in cells exhibiting the most severe bud elongation
(data not shown), suggesting that Acm1 may act to protect a
FIG. 5. Acm1 suppresses APC/CCdh1 activity in vivo. (A) Liquid YKA150 cultures harboring empty control plasmids or single-copy GAL1
promoter-driven expression plasmids (pHLP163 for 3FLAG-CDH1 and pHLP109 for HA-ACM1) were grown in selective raffinose medium, and
10-fold serial dilutions were spotted and grown on selective medium containing either glucose or galactose as the carbon source. (B) Same
experiment as in panel A with pHLP154 expressing 3FLAG-cdh1-m11 from the attenuated GALS promoter and pHLP112 expressing 3FLAG-
ACM1 from the GAL1 promoter. (C) BY4741 (wild-type) and sic1 cells containing empty control plasmids or single-copy GAL1 promoter-driven
expression plasmids (pHLP112 for 3FLAG-ACM1 and pHLP162 for 3FLAG-Cdh1) were grown and processed as in panel A.























specific subpopulation of Clb2 from APC/CCdh1-mediated pro-
teolysis (see Discussion).
Effects of acm1 on cells expressing endogenous Cdh1. Even
with endogenous Cdh1 expression, acm1 hsl1 cells exhibited a
more pronounced polarized growth phenotype than either single-
deletion strain (Fig. 7K and G, compare to panels E and C),
although not nearly to the same extent as with overexpressed
Cdh1. To further explore a possible cell cycle defect associated
with acm1 at the endogenous Cdh1 level, we examined cell cycle
distribution in a panel of yeast strains by flow cytometry. The cell
cycle profile of acm1 cells was very similar to that of wild-type
cells (Fig. 8). hsl1 cells exhibited a mild G2/M delay. The acm1
hsl1 double-deletion strain had a much more pronounced G2/M
delay than the hsl1 single-deletion mutant. This synergistic effect
was of a magnitude similar to that of the delay observed in a clb2
strain. Moreover, the G2/M delay in acm1 hsl1 double-deletion
cells was the same as in the clb2 single-mutant strain. These
results closely mirror the bud elongation results in Fig. 7, and
FIG. 6. Deletion of ACM1 in cells moderately overexpressing Cdh1 results in hyperpolarized growth independent of the morphogenesis
checkpoint. (A to I) Cells from HU-treated cultures of BY4741 (wild-type), YKA237 (acm1), and YKA255 (acm1 swe1) harboring an empty
plasmid or a plasmid overexpressing the 3FLAG-Cdh1 (pHLP130) or the 3FLAG-Cdh1IR mutant (pHLP120) from the ADH promoter were
visualized by DIC microscopy. Black arrows indicate examples of hyperpolarized buds. The percentage of cells containing an elongated bud is
shown in each panel and was determined by manual inspection of approximately 500 cells. The scale bar equals 32 m. A 40 objective lens was
used. (J) Co-IP of Clb2 with 3FLAG-Cdh1 (wild type [wt]) and 3FLAG-Cdh1IR (IR) from HU-arrested YKA237 cells. IP, immunoprecipitate.
(K) Immunoblotting of extracts from strains shown in panels A to I with anti-FLAG antibody to visualize overexpressed 3FLAG-Cdh1 and
3FLAG-Cdh1IR. Cdc28 was a loading control. WT, wild type.























FIG. 7. ACM1 interacts genetically with HSL1. (A to J) Cells from asynchronous mid-log-phase cultures of BY4741 with the indicated
genotypes and either pHLP130 expressing 3FLAG-Cdh1 from the ADH promoter or an empty plasmid control were visualized by DIC microscopy.
Scale bar, 32 m. A 40 objective lens was used. The percentage of elongated cells is indicated in the top left corner of each panel (n  500
for all panels except H, where n  300) and was obtained from images compiled from three independent experiments. Cells were counted as
elongated if their length was at least twice their width. (K) Frequency distributions of length/width ratio for the cells pictured in panels A to J
obtained from careful measurements of at least 100 randomly selected cells each. Open bars represent cells with the empty-plasmid control, and
solid bars represent cells with the 3FLAG-Cdh1 expression plasmid.























together they suggest that Acm1 and Hsl1 are independent pos-
itive regulators of mitotic CDK.
ACM1 is conserved in budding yeast species. Cdh1 and 14-
3-3 proteins are highly conserved in eukaryotes, prompting us
to search for homologs of Acm1 in other eukaryotic organisms.
Standard BLAST searches did not reveal any related proteins.
However, iterative PSI-BLAST searching revealed apparent
orthologs in several other budding yeasts (order Saccharomy-
cetales), including species such as Candida albicans and
Debaryomyces hansenii that are only distantly related to S.
cerevisiae within this group (see Fig. S1 in the supplemental
material). The fission yeast Schizosaccharomyces pombe does
not appear to have an Acm1 homolog, and we did not find any
homologs in any non-yeast species. The most highly conserved
sequence elements in Acm1 and its homologs include several
consensus CDK recognition sites (S/T-P-X-K/R), primarily
concentrated near the amino terminus. We have identified a
number of prominent phosphorylation sites, including several
at these consensus CDK sequences, by MS (D. Jeong and M.
Hall, unpublished data). These results and the evolutionary
conservation of the consensus CDK recognition sequences sug-
gest that Acm1 is likely regulated by CDK phosphorylation. In
addition, Acm1 has several sequences that match degrons com-
mon to APC/C substrates including three D box sequences
(R-x-x-L) and a KEN box. We are currently testing if Acm1
proteolysis is APC/C dependent.
DISCUSSION
A cell cycle-regulated complex associates with Cdh1. We
have identified a protein complex associated with the APC/C
coactivator Cdh1 and demonstrated that this complex is a
negative regulator of APC/CCdh1 function in vivo. In addition
to Cdh1, the complex contains the budding yeast 14-3-3 ho-
mologs Bmh1 and Bmh2 and a previously uncharacterized
protein, which we named Acm1. Acm1 appears to be the crit-
ical subunit for regulating assembly and dissociation of the
Cdh1 complex. Acm1 is cell cycle regulated, appearing in late
G1 and disappearing in late mitosis, and is required for stable
interaction between Cdh1 and the 14-3-3 proteins. As a result,
the Cdh1-Bmh1/Bmh2 interaction is restricted to the cell cycle
interval in which Acm1 is expressed. In S-phase-arrested cells,
the majority of Cdh1 is associated with this complex.
Knowledge of YPL267W (ACM1) prior to this study was
limited to a number of large-scale genomic and proteomic
screens. In addition to the global gene expression data already
mentioned, the product of YPL267W was identified as an in
vitro substrate of Clb2-Cdc28 in a proteomic screen for targets
of the mitotic CDK in budding yeast (53). Alignment of Acm1
with orthologs in other budding yeast species suggests that
CDK phosphorylation is likely conserved. We are currently
studying the function of Acm1 phosphorylation sites in regu-
lating the Cdh1 complex. The product of YPL267W (ACM1)
was also identified as a binding partner of the cyclins Cln2 and
Clb3 in another proteomic study (3).
The 14-3-3 family is highly conserved in eukaryotes. Bmh1
and Bmh2 share over 90% sequence identity with each other
and 70% identity with the human epsilon 14-3-3 isoform (19).
14-3-3 proteins function primarily as homo- and heterodimers,
interact with numerous proteins involved in diverse biological
processes, and exhibit a strong preference for phosphorylated
binding targets (54). Neither BMH1 nor BMH2 is an essential
gene, but loss of both is lethal in most strain backgrounds. In
many processes, they perform redundant functions. We predict
FIG. 8. Cell cycle distribution in acm1 hsl1 cells expressing endogenous Cdh1. (A) Yeast strains (BY4741 background) with the indicated
genotypes were grown to mid-log phase and analyzed by flow cytometry. n  genomic DNA content. (B) Data from panel A were analyzed with
ModFit LT software to determine the percentages of cells in G1, S, and G2/M. Percent G1 content is plotted for each strain. Data represent the
average of three independent cultures, and error bars are standard deviations. wt, wild type.























that Bmh1 and Bmh2 homo- or heterodimers bind to one or
more phosphorylation sites on Acm1, and we are currently
investigating this possibility.
Bud neck localization and substrate binding. One of the
many reported functions of 14-3-3 proteins is the cytoplasmic
sequestration of binding targets. Such regulation of cellular
localization by the 14-3-3 family has been described for several
proteins involved in cell cycle control (54). Our results suggest
that Bmh1 and Bmh2 are not required for cytoplasmic local-
ization of Cdh1. Instead, we found that the complex prevents
localization of Cdh1 to the bud neck (Fig. 3). Several Cdh1
substrates also localize to the bud neck, including Clb2 and
Hsl1, and we found that association of Cdh1 with these two
substrates was strongly enhanced in the absence of Acm1 in
S-phase-arrested cells. Cdh1 currently has no known function
at the bud neck. It is possible that Cdh1 transiently localizes to
the bud neck at a specific time during normal cell cycle pro-
gression or in response to cell cycle perturbations and that
Acm1/Bmh1/Bmh2 regulates its localization and function
there. Alternatively, it is possible that Acm1/Bmh1/Bmh2
merely acts to prevent Cdh1 localization to the bud neck dur-
ing the cell cycle interval in which Cdh1 is located in the
cytoplasm. Because the Acm1 protein may be specific to bud-
ding yeast species (based on our similarity searches), one can
speculate that it might regulate a Cdh1-dependent function
unique to budding yeast.
Based on the enhanced association of Cdh1 with Clb2 and
Hsl1 in the absence of Acm1, we predict that Acm1 acts, at
least in part, by preventing binding of specific substrates to
Cdh1 similar to the mechanism demonstrated for the verte-
brate Cdh1 and Cdc20 inhibitor Emi1 (41). The stable stoi-
chiometric interaction between Acm1 and Cdh1 (Fig. 1) is
consistent with this possibility. In addition, we found that ex-
pression of just the WD40 region of Cdh1, which has been
shown to be the site of substrate binding (28), was sufficient for
assembly of the intact complex with Acm1, Bmh1, and Bmh2
(our unpublished observations). A roughly 40-kDa Cdh1 pro-
teolytic fragment that copurifies with 3HA-Acm1 (labeled in
Fig. 1B) comprises the intact C-terminal WD40 domain. In
vitro experiments will ultimately be required to study how this
complex affects substrate binding to Cdh1.
Acm1 can negatively regulate APC/CCdh1 function in vivo.
We have presented several lines of evidence that strongly sug-
gest that Acm1 is able to inhibit APC/CCdh1-dependent prote-
olysis of mitotic cyclins in vivo. Overexpression of Acm1 re-
stored viability to cells expressing toxic levels of Cdh1 and the
Cdh1-m11 mutant lacking inhibitory CDK phosphorylation
sites. Lethality following high-level Cdh1 overexpression or in
the presence of Cdh1-m11 has previously been attributed to
inappropriate APC/C-mediated proteolysis of Clb2 (46, 56,
60), and we therefore conclude that rescue of this lethality by
Acm1 indicates suppression of APC/CCdh1-mediated proteol-
ysis of Clb2. Importantly, in the absence of CDK inhibition of
Cdh1, Acm1 is capable of fulfilling the role of APC/CCdh1
inhibitor to allow continued cell cycle progression, suggesting
overlapping or partly redundant functions. Synthetic lethality
of cdh1 with sic1 has previously been attributed to an in-
ability of cells to inactivate Clb2-Cdc28 activity at mitotic exit
(46, 56), and our finding that Acm1 overexpression is toxic in
a sic1 strain provides further evidence that Acm1 can sup-
press APC/CCdh1-dependent proteolysis of Clb2. Finally, this
conclusion is supported by our observations that (i) acm1
exacerbates another phenotype (hyperpolarized growth) asso-
ciated with deficient mitotic CDK activity in an APC/CCdh1
activity-dependent manner and (ii) ACM1 interacts genetically
with HSL1, which encodes a positive regulator of mitotic CDK,
resulting in synergistic hyperpolarization and G2/M cell cycle
delay in the absence of both.
Whether Acm1/Bmh1/Bmh2 represents a general negative
regulator of APC/CCdh1-catalyzed ubiquitination remains to be
seen. In light of the data reported here, we favor a model in
which Acm1 acts as a specialized inhibitor of mitotic cyclin
proteolysis. This is consistent with our observation that single
deletion of ACM1 to prevent formation of the complex has no
significant effect on cell cycle progression and growth (Fig. 8
and data not shown). Thus, the complex does not appear to be
required for regulation of APC/CCdh1 activity during standard
laboratory growth but perhaps performs a more specialized
function related to cell cycle progression under specific condi-
tions. Interestingly, Surana and colleagues recently reported
that in yeast unable to activate mitotic CDK by dephosphory-
lation of Cdc28 tyrosine 19, certain substrates of APC/CCdh1
remain sensitive to proteolysis whereas Clb2 is stable (14).
Perhaps Acm1 contributes to this apparent difference in APC/
CCdh1 substrate stability.
It is also apparent from our studies that absence of Acm1
does not result in massive depletion of Clb2, even when Cdh1
is overexpressed from the ADH promoter. This is in contrast to
previous studies that demonstrated rapid loss of Clb2 following
high-level galactose-induced Cdh1 expression (46, 56). We ex-
pected to find that Clb2 was lost or severely depleted in the
acm1 hsl1 cells that showed the most severe hyperpolariza-
tion and growth defect (Fig. 7). Surprisingly, the Clb2 level was
relatively high in these cells (not shown). This suggests that
under these experimental conditions Cdh1 may be targeting
only a subpopulation of Clb2 for proteolysis in the absence of
Acm1 (e.g., the population located at the bud neck or in the
cytoplasm) and this fraction of total cellular Clb2 is important
for promoting isotropic bud growth and mitotic entry. It is
important to note that Cdh1 is primarily cytoplasmic outside
G1 phase and thus the nuclear population of Clb2 could be
protected from Cdh1 during this time. Although the formal
possibility exists that Cdh1 is simply interfering with Clb2-
Cdc28 function by inappropriately binding to Clb2, our exper-
iments with the cdh1IR allele argue against it. The fact that
the phenotypes observed when wild-type Cdh1 is overex-
pressed are greatly diminished with Cdh1IR, which binds
substrates but is unable to activate APC/C (10, 37, 58), suggests
that APC/C-mediated proteolysis is required.
The significance of the enhanced interaction between Cdh1
and Hsl1 in acm1 cells is not clear. Inappropriate Hsl1 deg-
radation in the absence of Acm1 seems unlikely because it
should result in stabilization of Swe1, which would contribute
to the elongated-bud phenotype. Instead, the effects we ob-
served on bud elongation were clearly SWE1 independent.
Perhaps the effects on Hsl1 are minimal and secondary com-
pared to those on Clb2 and do not perturb the regulation of
Swe1 enough to influence bud morphology. Like Clb2, Hsl1
was not significantly depleted in acm1 cells overexpressing
Cdh1 (not shown).























What is the biological function of Acm1? It is unclear why
Cdh1 is not eliminated from cells after its G1 function is com-
plete, especially since a convenient mechanism seems to al-
ready be in place to do so. Sic1 protein plays a redundant role
with Cdh1 in promoting mitotic exit by stoichiometrically in-
hibiting mitotic CDK activity (48). Sic1 is phosphorylated on
multiple sites in a G1 CDK-dependent manner in the following
cell cycle (45), resulting in its recognition and polyubiquitina-
tion by the SCFCdc4 ubiquitin ligase (17) and consequent pro-
teolysis. Cdh1 is inactivated around the same time as Sic1, also
by multisite CDK phosphorylation (26, 60). However, it is not
eliminated by proteolysis. Instead, it is exported to the cyto-
plasm and its level stabilizes (23, 25, 60). A similar expression
pattern is found in higher eukaryotic cells (31). This persis-
tence of Cdh1 after the G1/S transition suggests that it might be
required for an as-yet-unidentified function during S, G2,
and/or early M. Perhaps the association with Acm1, Bmh1, and
Bmh2 stabilizes Cdh1 and maintains it in an inactive state
following G1 exit such that APC/C
Cdh1 activity can be activated
in response to a specific signal.
What type of signal would be expected to activate APC/
CCdh1 in S phase or early M? The elongated-bud phenotypes
observed when we overexpress Cdh1 in an acm1 background
are reminiscent of the hyperpolarized cell morphology seen in
pseudohyphal yeast. The switch from the yeast form to fila-
mentous growth is believed to involve down-regulation of mi-
totic CDK activity that allows an extended polarized growth
period, resulting in the highly elongated cells found in
pseudohyphae (1). In fact, it has been proposed that a distinct
inhibitor of Clb2-Cdc28 activity might exist to elicit this re-
sponse (1). Components of the morphogenesis checkpoint,
including Hsl1 and Swe1, are involved in controlling the switch
to filamentous growth (15), and a role for APC/CCdh1 in this
process is conceivable. Moreover, Bmh1 and Bmh2 have been
implicated in the filamentous growth response as regulators of
the Ste20 protein (43). Another possible function for Cdh1
could be down-regulation of Clb-Cdc28 activity in response to
a checkpoint signal that occurs in S, G2, or early M and that
contributes to cell cycle arrest. Other possibilities exist as well,
including effects of Cdh1 on substrates other than Clb2. We are
currently testing a variety of possibilities in an effort to define
the biological significance of Acm1 and its association with
Cdh1 and the biochemical mechanism by which it inhibits
APC/CCdh1.
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